Cargando…
Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403831/ https://www.ncbi.nlm.nih.gov/pubmed/32508050 http://dx.doi.org/10.1002/ctm2.53 |
| _version_ | 1783567018883022848 |
|---|---|
| author | Yu, Yunfang Chen, Yongjian Li, Anlin Ou, Qiyun Li, Qingjian Gu, Yang Lin, Dagui Zhang, Wenda Wang, Jingshu Tang, Xudong Li, Zhihua Hu, Hai Yao, Herui |
| author_facet | Yu, Yunfang Chen, Yongjian Li, Anlin Ou, Qiyun Li, Qingjian Gu, Yang Lin, Dagui Zhang, Wenda Wang, Jingshu Tang, Xudong Li, Zhihua Hu, Hai Yao, Herui |
| author_sort | Yu, Yunfang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7403831 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74038312020-08-06 Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials Yu, Yunfang Chen, Yongjian Li, Anlin Ou, Qiyun Li, Qingjian Gu, Yang Lin, Dagui Zhang, Wenda Wang, Jingshu Tang, Xudong Li, Zhihua Hu, Hai Yao, Herui Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2020-06-05 /pmc/articles/PMC7403831/ /pubmed/32508050 http://dx.doi.org/10.1002/ctm2.53 Text en © 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to Editor Yu, Yunfang Chen, Yongjian Li, Anlin Ou, Qiyun Li, Qingjian Gu, Yang Lin, Dagui Zhang, Wenda Wang, Jingshu Tang, Xudong Li, Zhihua Hu, Hai Yao, Herui Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title | Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title_full | Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title_fullStr | Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title_full_unstemmed | Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title_short | Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials |
| title_sort | novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: results from two multicenter, randomized clinical trials |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403831/ https://www.ncbi.nlm.nih.gov/pubmed/32508050 http://dx.doi.org/10.1002/ctm2.53 |
| work_keys_str_mv | AT yuyunfang novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT chenyongjian novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT lianlin novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT ouqiyun novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT liqingjian novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT guyang novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT lindagui novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT zhangwenda novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT wangjingshu novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT tangxudong novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT lizhihua novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT huhai novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials AT yaoherui novelbloodbasedtumormutationalgorithmandnomogrampredictsurvivalofimmunecheckpointinhibitorinnonsmallcelllungcancerresultsfromtwomulticenterrandomizedclinicaltrials |